See original article in english Antitrust in Life Sciences #3 Generics: Pay-For-Delay, Patent Settlements, Reverse Payment, Price-Fixing & Market Allocation

Webinar

Antitrust in Life Sciences #3 Generics : Pay-For-Delay, Patent Settlements, Reverse Payment, Price-Fixing & Market Allocation

3ème webinaire de la conférence « Antitrust in Life Sciences 2021 » organisé par Concurrences, en partenariat avec NERA Economic Consulting et White & Case, avec Molly Herron (Lead Group Antitrust Counsel, - ex-Americas, Novartis), Ginger Jin (Professeur, Université du Maryland), Christine Meyer (Chair, Intellectual Property Practice & Managing Director, NERA Economic Consulting) et Robert Milne (Associé, White & Case).

- Vidéo : Accessible aux abonnés Concurrences+ (voir ci-dessous)

- Audio : Accessible aux abonnés Concurrences+ (voir ci-dessous)

- Synthèse : Accessible aux abonnés Concurrences+ (voir ci-dessus)

- Retranscription : Accessible aux abonnés Concurrences+ (voir ci-dessus)

- Documentation liée à l’événement (Cliquez sur Voir plus ci-dessous)

- Articles Concurrences (Cliquez sur Voir plus ci-dessous)

Consultez la section "Prochaines Conferences" pour vous inscrire aux futurs webinaires.


SYNTHÈSE

Ginger Jin moderated this session. She pointed that patent settlement between brand name and generic drug makers has been an important area of IP protection and antitrust enforcement, as highlighted by the ongoing debate about pay-for-delay agreements. When the U.S. Supreme Court issued its 2013 decision in FTC v. Actavis both sides claimed victory. Eight years later, the decision has reshaped business practice in this area.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

Speakers

Testimonial